Cancer immunotherapy drugs only work for a minority of patients, but a generic drug now used to increase blood flow may be able to improve those odds, a study by Columbia University Medical Center researchers suggests.
The Columbia Combined Cancer Panel has been granted full approval by the New York State Department of Health.
Dr. Naiyer Rizvi, director of thoracic oncology at CUMC, offers updates on immune checkpoint inhibitors in certain forms of lung cancers.
Columbia scientists have created new decoy drugs that can intercept the deceptive growth signals that cancer cells send out.
A study of the genomes of patients with a particularly aggressive form of non-Hodgkin’s lymphoma shows that many cases are driven by alterations in the JAK/STAT3 cell signaling pathway.
Nearly 50 years after the “war on cancer” was declared in the United States, precision medicine is changing the face of cancer research.